

Panithaya Chareonthaitawee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9784404/publications.pdf>

Version: 2024-02-01

35
papers

1,187
citations

687363

13
h-index

454955

30
g-index

37
all docs

37
docs citations

37
times ranked

1313
citing authors

#	ARTICLE	IF	CITATIONS
1	Joint SNMMI&ASNC Expert Consensus Document on the Role of ¹⁸ F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1341-1353.	5.0	187
2	Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. <i>Journal of Nuclear Medicine</i> , 2018, 59, 273-293.	5.0	163
3	Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 269-297.	2.1	151
4	Joint SNMMI&ASNC expert consensus document on the role of ¹⁸ F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1741-1758.	2.1	132
5	Artificial Intelligence in Cardiology: Present and Future. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1015-1039.	3.0	127
6	Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 1136-1146.	2.1	121
7	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1267.	6.1	66
8	Successful use of rituximab in refractory cardiac sarcoidosis. <i>Rheumatology</i> , 2016, 55, 189-191.	1.9	36
9	Myocardial Energetics in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006240.	3.9	29
10	Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease. <i>International Journal of Cardiology</i> , 2021, 335, 66-72.	1.7	26
11	PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers. <i>Pharmaceuticals</i> , 2021, 14, 1286.	3.8	26
12	Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience. <i>Journal of Cardiac Failure</i> , 2022, 28, 247-258.	1.7	16
13	Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 6-14.	5.0	13
14	Phase analysis single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) detects dyssynchrony in myocardial scar and increases specificity of MPI. <i>EJNMMI Research</i> , 2019, 9, 11.	2.5	9
15	Imaging and Quantification of Cardiac Sarcoidosis. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 283-294.	4.6	9
16	Patient page-sarcoidosis imaging. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 222-226.	2.1	7
17	Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis on Frequency of Venous Thromboembolism. <i>American Journal of Cardiology</i> , 2021, 149, 112-118.	1.6	5
18	The impact of combined cardiopulmonary exercise testing and SPECT myocardial perfusion imaging on downstream evaluation and management. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 92-106.	2.1	4

#	ARTICLE	IF	CITATIONS
19	18F-FDG/13N-ammonia cardiac PET findings in ATTR cardiac amyloidosis. Journal of Nuclear Cardiology, 2023, 30, 726-735.	2.1	4
20	Unraveling Inflammation and Oxidative Stress in Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	2
21	Exercise-Induced Left Bundle Branch Block Resulting in Severe Mitral Regurgitation. JACC: Case Reports, 2021, 3, 1287-1290.	0.6	2
22	Reply: Role of ¹⁸ F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring: Addition to the Expert Consensus. Journal of Nuclear Medicine, 2019, 60, 293-294.	5.0	2
23	Imaging cardiac sarcoidosis and infiltrative diseases: diagnosis and therapeutic response. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 51-73.	0.7	2
24	Metastatic breast cancer diagnosed by rubidium-82 positron emission tomography myocardial perfusion imaging. Journal of Nuclear Cardiology, 2018, 25, 1048-1050.	2.1	1
25	Diagnostic performance of F18 FDG PET in cardiac sarcoidosis: Are we getting closer to the truth?. Journal of Nuclear Cardiology, 2020, 27, 2116-2117.	2.1	1
26	Can we REFINE stress-only SPECT MPI protocols using machine learning?. Journal of Nuclear Cardiology, 2022, 29, 2308-2310.	2.1	1
27	Utilization of cardiac imaging in sarcoidosis. Expert Review of Cardiovascular Therapy, 2022, , 1-14.	1.5	1
28	SNMMI/ACR/ASNC/SCMR joint credentialing statement for cardiac PET/MRI. Journal of Cardiovascular Magnetic Resonance, 2022, 24, .	3.3	1
29	¹²³ I- <i>Meta</i> -Iodobenzylguanidine Guanidineâ€“Guided Ventricular Tachycardia Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 520-522.	4.8	0
30	Fluorine-18 fluorodeoxyglucose positron emission tomography for cardiac sarcoidosisâ€”is it time to consider a new radiotracer?. EJNMMI Research, 2017, 7, 70.	2.5	0
31	Positron emission tomography for diagnosis of prosthetic valve endocarditis. Journal of Nuclear Cardiology, 2019, 26, 677-678.	2.1	0
32	Correlation of ¹⁸ F-NaF Activity With Progression of Macrocalcification. Circulation: Cardiovascular Imaging, 2020, 13, e012095.	2.6	0
33	Cardiac sarcoidosis cases from a busy nuclear cardiology laboratory. Journal of Nuclear Cardiology, 2021, 28, 1553-1568.	2.1	0
34	Quantitative FDG PET/CT to Guide Treatment of Cardiac Sarcoidosis. JACC: Cardiovascular Imaging, 2021, 14, 2017-2019.	5.3	0
35	99mTechnetium-pyrophosphate cardiac scintigraphy cases from a busy nuclear cardiology laboratory. Journal of Nuclear Cardiology, 2022, 29, 2157-2167.	2.1	0